钠葡萄糖协同转运蛋白2抑制与肾脏血流动力学可视化 - Suppr

Suppr

超能文献

Sodium Glucose Cotransporter 2 Inhibition and the Visualization of Kidney Hemodynamics.

作者信息

Wanner Christoph

机构信息

Department of Medicine, Division of Nephrology, University Hospital Würzburg, Germany.

出版信息

Circulation. 2019 Jul 23;140(4):316-318. doi: 10.1161/CIRCULATIONAHA.119.040326. Epub 2019 Jul 22.

DOI:10.1161/CIRCULATIONAHA.119.040326

PMID:31329485

Abstract

摘要

相似文献

Sodium Glucose Cotransporter 2 Inhibition and the Visualization of Kidney Hemodynamics.钠葡萄糖协同转运蛋白2抑制与肾脏血流动力学可视化

Circulation. 2019 Jul 23;140(4):316-318. doi: 10.1161/CIRCULATIONAHA.119.040326. Epub 2019 Jul 22.

Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging.利用体内成像技术评价恩格列净对糖尿病小鼠肾小球血流动力学的影响。

Circulation. 2019 Jul 23;140(4):303-315. doi: 10.1161/CIRCULATIONAHA.118.037418. Epub 2019 Feb 18.

Do sodium-glucose cotransporter-2 inhibitors affect renal hemodynamics by different mechanisms in type 1 and type 2 diabetes?钠-葡萄糖共转运蛋白 2 抑制剂在 1 型和 2 型糖尿病中通过不同机制影响肾血流动力学吗？

Kidney Int. 2020 Jan;97(1):31-33. doi: 10.1016/j.kint.2019.09.023.

Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease?钠-葡萄糖协同转运蛋白2（SGLT2）抑制可减轻肾小球高滤过：SGLT2抑制剂在糖尿病肾病中是否发挥作用？

Circulation. 2014 Feb 4;129(5):542-4. doi: 10.1161/CIRCULATIONAHA.113.007071. Epub 2013 Dec 13.

Sodium Glucose Cotransporter 2 Inhibitors: Searching for Mechanisms in the Wake of Large, Positive Cardiovascular Outcomes Trials.

Circulation. 2019 Nov 19;140(21):1703-1705. doi: 10.1161/CIRCULATIONAHA.119.043487. Epub 2019 Nov 18.

Diving into the unknown: sodium-glucose cotransporter-2 inhibitors in heart failure without diabetes.探索未知：钠-葡萄糖协同转运蛋白2抑制剂在非糖尿病性心力衰竭中的应用

Eur J Heart Fail. 2019 Jul;21(7):874-876. doi: 10.1002/ejhf.1500. Epub 2019 May 21.

Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.选择性钠-葡萄糖协同转运蛋白2抑制剂恩格列净对2型糖尿病患者血管功能和中心血流动力学的影响。

Circulation. 2017 Sep 19;136(12):1167-1169. doi: 10.1161/CIRCULATIONAHA.117.029529.

Is the joint use of diuretics and SGLT2 inhibitors beneficial in diabetic kidney disease?利尿剂和SGLT2抑制剂联合使用对糖尿病肾病有益吗？

Kidney Int. 2020 Jan;97(1):213. doi: 10.1016/j.kint.2019.08.039.

SGLT2 Inhibitors and the Diabetic Kidney.钠-葡萄糖协同转运蛋白 2 抑制剂与糖尿病肾脏疾病

Diabetes Care. 2016 Aug;39 Suppl 2:S165-71. doi: 10.2337/dcS15-3006.

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.恩格列净与 2 型糖尿病、已确诊心血管疾病和慢性肾脏病患者的临床结局。

Circulation. 2018 Jan 9;137(2):119-129. doi: 10.1161/CIRCULATIONAHA.117.028268. Epub 2017 Sep 13.

引用本文的文献

Sodium-Glucose Transporter 2 (SGLT2) Inhibitors and Iron Deficiency in Heart Failure and Chronic Kidney Disease: A Literature Review.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂与心力衰竭和慢性肾脏病中的缺铁：一项文献综述

Life (Basel). 2023 Dec 13;13(12):2338. doi: 10.3390/life13122338.

Renoprotective effects of empagliflozin are linked to activation of the tubuloglomerular feedback mechanism and blunting of the complement system.恩格列净的肾保护作用与其激活管球反馈机制和抑制补体系统有关。

Am J Physiol Cell Physiol. 2023 Apr 1;324(4):C951-C962. doi: 10.1152/ajpcell.00528.2022. Epub 2023 Feb 13.

Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation.SGLT2抑制剂的器官保护作用：代谢能量和节水的作用

Nat Rev Nephrol. 2021 Jan;17(1):65-77. doi: 10.1038/s41581-020-00350-x. Epub 2020 Oct 1.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验